Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dexpanthenol foam, new formulation · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Dexpanthenol foam spray, new formulation | DRUG | 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter |
| Dexpanthenol foam spray, old formulation | DRUG | 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter |
Inclusion Criteria: * Healthy subjects * Phototype: I to IV according to Fitzpatrick scale Exclusion Criteria: * Pregnant or nursing women * Subjects registered as being in exclusion period in the French Health Minister file of subjects * Subjects with known allergy to cosmetics, skin care produc...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
Dexpanthenol foam, new formulation is an investigational small molecule being studied for dermatology conditions including skin abnormalities and erythema, or redness of the skin. It is being developed by Bayer AG (ticker: BAYRY) and is currently in Phase 2 clinical development.
Dexpanthenol foam, new formulation is being developed by Bayer AG, a pharmaceutical company traded under the ticker BAYRY. The drug is in Phase 2 clinical development for dermatology indications such as skin abnormalities and erythema.
Dexpanthenol foam, new formulation is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for skin abnormalities and erythema.
Dexpanthenol foam, new formulation has been studied in two completed Phase 2 clinical trials. NCT00839280 evaluated its moisturizing effect in 19 healthy volunteers with skin abnormalities in France. NCT00839462 assessed its efficacy in 55 healthy volunteers with erythema in France. Both trials were randomized, double-blind, and active-controlled.
Dexpanthenol foam, new formulation is a formulation of dexpanthenol, a small molecule. The clinical trials NCT00839280 and NCT00839462 studied the moisturizing and anti-redness effects of this specific foam formulation in healthy volunteers with skin abnormalities and erythema.